{"_id": "65013becfddc0bb1312fb042", "and": 8, "prostate cancer histology": 1, "prostate cancer progression on androgen deprivation therapy": 1, "metastatic disease": 1, "bone lesions": 1, "soft tissue disease": 1, "abiraterone acetate exposure": 1, "androgen deprivation": 1, "bone resorptive therapy": 1, "refrain from donating sperm": 1, "be abstinent": 1, "must agree to use male condom": 1, "biopsy sample": 1, "soft tissue biopsy": 1, "bone biopsy": 1, "ECOG performance status": 1, "additional malignancy": 1, "autoimmune disease": 1, "immunodeficiency": 1, "major surgery": 1, "gastrointestinal disorder": 1, "active infection": 1, "pneumonitis/interstitial lung disease": 1, "HIV infection": 1, "CNS metastases": 1, "hypersensitivity": 1, "seizure history": 1, "loss of consciousness history": 1, "hypotension": 1, "bradycardia": 1, "ketoconazole treatment": 1, "prior anti-PD-1/PD-L1/PD-L2 therapy": 1, "prior radium or radiopharmaceutical treatment": 1, "prior docetaxel or chemotherapy treatment": 1, "prior anti-cancer monoclonal antibody therapy": 1, "herbal product use": 1, "live vaccine use": 1, "participation in investigational study": 1, "'superscan' bone scan": 1, "expecting to conceive or father children": 1, "allogenic tissue/solid organ transplant": 1, "nctId": 10, "cancer type": 5, "histologically confirmed diagnosis": 1, "days since surgical resection": 1, "Karnofsky performance status": 1, "adequate organ function": 3, "resting baseline O2 saturation by pulse oximetry": 1, "able to provide written informed consent/assent": 1, "life expectancy": 1, "willingness to discontinue medications associated with risk of Torsades de Pointes": 1, "medications associated with risk of Torsades de Pointes": 1, "lesion size": 1, "prior anti-cancer therapy for glioblastoma": 1, "negative urine or serum pregnancy test for females of childbearing potential": 1, "urine test result": 1, "serum pregnancy test required": 1, "adequate method of contraception for females and males of childbearing potential": 1, "abstinence is acceptable": 1, "use of Optune device": 1, "prior treatment of glioblastoma with radiation and temozolomide": 1, "evidence of leptomeningeal disease": 1, "prior treatment with Gliadel": 1, "unable or unwilling to have a contrast enhanced MRI of brain": 1, "currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment": 1, "diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment": 1, "physiologic doses of steroid therapy by the time of first dose of treatment are allowed": 1, "known history of active Bacillus Tuberculosis": 1, "hypersensitivity to pembrolizumab or any of its excipients": 1, "prior anti-cancer monoclonal antibody within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 weeks earlier": 1, "potential participants with \u2264 Grade 2 neuropathy may qualify for the study": 1, "prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent": 1, "if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy": 1, "known additional malignancy that is progressing or requires active treatment": 1, "basal cell carcinoma of the skin that has undergone potentially curative therapy": 1, "squamous cell carcinoma of the skin that has undergone potentially curative therapy": 1, "in situ cervical cancer": 1, "active autoimmune disease that has required systemic treatment in the past 2 years": 1, "use of disease modifying agents": 1, "corticosteroids": 1, "immunosuppressive drugs": 1, "known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy": 1, "active serious infection requiring systemic therapy": 1, "major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study": 1, "history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate": 1, "known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial": 1, "is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial": 1, "starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment": 1, "prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent": 1, "known history of Human Immunodeficiency Virus": 1, "known active Hepatitis B or Hepatitis C": 1, "received a live vaccine within 30 days of planned start of study therapy": 1, "HER2 amplification/overexpression": 1, "uterine serous carcinoma": 1, "HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification": 1, "treatment history": 1, "clinical trial participation": 1, "performance status": 1, "primary site": 1, "days since surgery": 1, "biopsy under general anesthesia": 1, "extracapsular nodal extension": 1, "invasive cancer at resection margin": 1, "pathologic stage": 1, "distant metastases": 1, "last examination by radiation oncologist or medical oncologist": 1, "last examination by ENT or head & neck surgeon": 1, "last neck CT scan": 1, "last chest CT scan": 1, "Zubrod performance status": 2, "age": 4, "absolute granulocyte count": 1, "platelets": 2, "hemoglobin": 1, "total bilirubin": 2, "AST": 1, "serum creatinine": 1, "creatinine clearance": 1, "negative pregnancy test": 1, "sodium": 1, "magnesium": 1, "magnesium supplementation": 1, "feeding tubes": 1, "effective birth control": 1, "informed consent": 2, "prior invasive malignancy": 1, "simultaneous primaries or bilateral tumors": 1, "prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy": 1, "prior radiotherapy to the region of the study cancer": 1, "unstable angina and/or congestive heart failure": 1, "transmural myocardial infarction": 1, "acute bacterial or fungal infection requiring intravenous antibiotics": 1, "chronic obstructive pulmonary disease exacerbation or other respiratory illness": 1, "idiopathic pulmonary fibrosis or other severe interstitial lung disease": 1, "hepatic insufficiency resulting in clinical jaundice and/or coagulation defects": 1, "acquired immune deficiency syndrome (AIDS)": 1, "grade 3-4 electrolyte abnormalities": 1, "pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception": 1, "prior allergic reaction to cetuximab": 1, "metastasis to brain": 1, "primary tumor origin": 1, "BRAF-V600 mutation": 1, "days since brain MRI": 1, "brain metastasis size": 1, "MRI slice thickness": 1, "CT of head": 1, "CNS disease documented": 1, "extracranial disease": 1, "disease assessment documented": 1, "leptomeningeal disease": 1, "corticosteroids dose": 1, "days since history and physical examination": 1, "able to swallow and retain pills": 1, "Hemoglobin": 2, "Absolute neutrophil count": 1, "Platelets": 1, "Total bilirubin": 2, "AST and ALT": 1, "Creatinine": 1, "cardiac risk assessment": 1, "prior or concurrent malignancy": 2, "HIV infection status": 1, "HCV infection status": 1, "image banking": 1, "specimen and blood collections": 1, "institutional review board approval": 1, "prior systemic therapy for metastatic disease": 1, "days since prior radiation therapy": 1, "additional systemic anti-tumor therapy": 1, "use of hormonal contraceptives": 1, "serious active infection": 1, "active autoimmune disease": 1, "immune-related adverse events": 1, "adverse events related to encorafenib and/or binimetinib": 1, "pregnant or nursing": 1, "consultation with the Medical Monitor": 2, "diagnosis": 3, "additional line of therapy with appropriate targeted therapy for patients with actionable mutations (other than EGFR, ALK, or ROS genomic alterations)": 2, "documented radiographic disease progression on or after the first-line therapy": 1, "concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab": 2, "no more than 1 prior line if ICI and platinum-based chemotherapy were administered concurrently": 2, "no more than 2 prior lines for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines": 2, "LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination": 1, "meet all eligibility criteria except documented disease progression": 2, "intend to receive TIL therapy after disease progression": 2, "prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy": 1, "count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy": 1, "resectable lesion for TIL production": 2, "remaining measurable lesion, as defined by RECIST v1.1": 1, "LVEF > 45%, NYHA Class 1": 2, "adequate pulmonary function": 2, "ECOG performance status of 0 or 1": 2, "patients of childbearing potential or those with partners of childbearing potential": 2, "willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy": 2, "EGFR driver mutation": 2, "ALK driver mutation": 2, "ROS driver mutation": 2, "symptomatic, untreated brain metastases": 2, "allogeneic organ transplant or prior cell therapy within the past 20 years": 2, "any form of primary immunodeficiency": 2, "on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent": 2, "received a live or attenuated vaccination within 28 days prior to the start of treatment": 2, "had another primary malignancy within the previous 3 years": 2, "participation in another interventional clinical study within 21 days": 2, "surgery": 1, "positive margins and/or extra nodal extension (ENE)": 1, "positive margins defined as malignancy at or within 1 mm of the margin": 1, "high grade dysplasia (i.e. carcinoma in situ) at the margin": 1, "ENE may be either gross or microscopic": 1, "PD-L1 Combined Positive Score (CPS)": 1, "prior radiation to the area of recurrent or second primary tumor": 1, "completed prior radiation a minimum of 6 months prior to randomization": 1, "no evidence of distant disease based on baseline imaging done within 28 days prior to randomization": 1, "no anti-PD-1/PD-L1 therapy for recurrent disease": 1, "Eastern Cooperative Oncology Group (ECOG) performance status": 1, "able to understand and willingness to sign a written informed consent document": 1, "not pregnant": 1, "not breastfeeding": 1, "not expecting to conceive or father children": 1, "using accepted and effective method(s) of contraception or abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment": 1, "ANC": 1, "Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)": 1, "Creatinine clearance": 1, "no current active infection that requires systemic treatment at time of randomization": 1, "no history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization": 1, "no history of solid organ transplant or stem cell transplant": 1, "not on immunosuppressive medication within 7 days prior to randomization": 1, "intranasal, inhaled, topical steroids, or local steroid injection": 1, "systemic corticosteroids at physiologic doses": 1, "steroids as premedication for hypersensitivity reactions": 1, "clinical risk assessment of cardiac function using the New York Heart Association Functional classification": 1, "no live vaccine within 30 days prior to the first dose of study drug": 1, "no severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients": 1, "no active autoimmune disease that has required systemic treatment in past 2 years": 1, "replacement therapy is not considered a form of systemic treatment": 1, "no known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study": 1, "HIV-infected patients on effective anti-retroviral therapy": 1, "undetectable viral load within 6 months": 1, "known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)": 1, "known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection": 1, "documented radiographic disease progression on or after first-line therapy": 1, "LN-145 manufacture allowed for patients with residual resectable disease after completion of platinum-based chemotherapy component of front-line ICI and platinum-based chemotherapy combination": 1, "prior systemic therapy in adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy": 1, "count as a line of therapy if patient had disease progression during or within 12 months after completion of such therapy": 1, "remaining measurable lesion as defined by RECIST v1.1": 1, "cancer stage": 1, "resectable": 1, "pathologically confirmed": 1, "nodal recurrence after surgery for early stage NSCLC": 1, "ECOG status": 1, "body weight": 1, "unintentional weight loss": 1, "baseline electrocardiography (ECG)": 1, "measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1": 1, "Absolute neutrophil count (ANC)": 1, "White blood cells (WBC) counts": 1, "Platelet count": 1, "Aspartate aminotransferase (AST) and alanine transaminase (ALT)": 1, "Serum creatinine": 1, "pulmonary function tests (PFTs) with both forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO)": 1, "lung volume (V)20": 1, "nodal recurrence after surgery for early-stage NSCLC": 1, "No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol": 1, "Prior curative-intent surgery was at least 90 days prior to the nodal recurrence": 1, "No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields": 1, "HIV positive": 1, "stable on their anti-retroviral regimen": 1, "healthy from an HIV perspective": 1, "CD4 count": 1, "not receiving prophylactic therapy for an opportunistic infection": 1, "potential to interfere with the safety or efficacy assessment of the investigational regimen": 1, "chemotherapy or radiotherapy within 4 weeks": 1, "nitrosoureas or mitomycin C within 6 weeks": 1, "not pregnant or breast-feeding": 1, "negative blood test or urine study": 1, "not expected to conceive or father children": 1, "not receiving non-protocol anti-cancer therapy after the end of Step 1 chemo/radiation or during Step 2 consolidation": 1}